CL2011002893A1 - Peptido derivado del factor viii; composicion que lo comprende; uso para aumentar la tolerancia a factor viii en individuos que padecen o estan en riesgo de padecer hemofilia a o hemofilia adquirida. - Google Patents

Peptido derivado del factor viii; composicion que lo comprende; uso para aumentar la tolerancia a factor viii en individuos que padecen o estan en riesgo de padecer hemofilia a o hemofilia adquirida.

Info

Publication number
CL2011002893A1
CL2011002893A1 CL2011002893A CL2011002893A CL2011002893A1 CL 2011002893 A1 CL2011002893 A1 CL 2011002893A1 CL 2011002893 A CL2011002893 A CL 2011002893A CL 2011002893 A CL2011002893 A CL 2011002893A CL 2011002893 A1 CL2011002893 A1 CL 2011002893A1
Authority
CL
Chile
Prior art keywords
factor viii
hemophilia
composition
peptide derived
risk
Prior art date
Application number
CL2011002893A
Other languages
English (en)
Inventor
David Wraith
Original Assignee
Apitope Int Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002893(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apitope Int Nv filed Critical Apitope Int Nv
Publication of CL2011002893A1 publication Critical patent/CL2011002893A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Péptido de secuencia EDNIMVTFRNQASR derivada del factor VIII (FVIII); composición que lo comprende; y uso para la preparación de un medicamento útil para suprimir o prevenir la producción de anticuerpos inhibidores del factor VIII in vivo y para tratar hemofilia adquirida.
CL2011002893A 2009-05-18 2011-11-17 Peptido derivado del factor viii; composicion que lo comprende; uso para aumentar la tolerancia a factor viii en individuos que padecen o estan en riesgo de padecer hemofilia a o hemofilia adquirida. CL2011002893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0908515.0A GB0908515D0 (en) 2009-05-18 2009-05-18 Peptide

Publications (1)

Publication Number Publication Date
CL2011002893A1 true CL2011002893A1 (es) 2012-08-17

Family

ID=40834163

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002893A CL2011002893A1 (es) 2009-05-18 2011-11-17 Peptido derivado del factor viii; composicion que lo comprende; uso para aumentar la tolerancia a factor viii en individuos que padecen o estan en riesgo de padecer hemofilia a o hemofilia adquirida.

Country Status (30)

Country Link
US (1) US8703705B2 (es)
EP (2) EP2465523B1 (es)
JP (1) JP5784009B2 (es)
KR (1) KR101673889B1 (es)
CN (1) CN102458445B (es)
AU (1) AU2010250957B2 (es)
BR (1) BRPI1012845A2 (es)
CA (1) CA2762020C (es)
CL (1) CL2011002893A1 (es)
CO (1) CO6460780A2 (es)
CY (1) CY1115832T1 (es)
DK (1) DK2465523T3 (es)
EA (1) EA027229B1 (es)
EC (1) ECSP11011540A (es)
ES (1) ES2525448T3 (es)
GB (1) GB0908515D0 (es)
HR (1) HRP20141182T1 (es)
IL (1) IL216199A (es)
MX (1) MX2011012270A (es)
MY (1) MY168207A (es)
NZ (2) NZ613713A (es)
PL (1) PL2465523T3 (es)
PT (1) PT2465523E (es)
RS (1) RS53671B1 (es)
SG (2) SG190573A1 (es)
SI (1) SI2465523T1 (es)
SM (1) SMT201400186B (es)
UA (1) UA110921C2 (es)
WO (1) WO2010133834A2 (es)
ZA (1) ZA201108446B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168124B2 (en) 2015-10-30 2021-11-09 Spark Therapeutics, Inc. CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disorders

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069164A2 (en) 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1918298T3 (da) 2000-08-21 2010-11-29 Apitope Technology Bristol Ltd Peptid
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002098454A2 (en) * 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2003087161A1 (en) * 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168124B2 (en) 2015-10-30 2021-11-09 Spark Therapeutics, Inc. CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disorders

Also Published As

Publication number Publication date
SI2465523T1 (sl) 2015-02-27
CO6460780A2 (es) 2012-06-15
US20120121625A1 (en) 2012-05-17
WO2010133834A2 (en) 2010-11-25
NZ596300A (en) 2013-08-30
HK1173358A1 (en) 2013-05-16
SG176138A1 (en) 2011-12-29
MY168207A (en) 2018-10-15
NZ613713A (en) 2014-10-31
PT2465523E (pt) 2014-12-09
WO2010133834A3 (en) 2011-02-24
IL216199A0 (en) 2012-01-31
JP2012527440A (ja) 2012-11-08
EA027229B1 (ru) 2017-07-31
EA201171430A1 (ru) 2012-05-30
MX2011012270A (es) 2011-12-12
US8703705B2 (en) 2014-04-22
GB0908515D0 (en) 2009-06-24
CN102458445A (zh) 2012-05-16
SMT201400186B (it) 2015-01-15
ECSP11011540A (es) 2012-01-31
AU2010250957B2 (en) 2015-01-15
CN102458445B (zh) 2014-06-11
AU2010250957A1 (en) 2011-12-01
CY1115832T1 (el) 2017-01-25
EP2465523B1 (en) 2014-10-01
CA2762020C (en) 2018-08-28
KR20120023023A (ko) 2012-03-12
UA110921C2 (uk) 2016-03-10
DK2465523T3 (en) 2014-12-15
HRP20141182T1 (hr) 2015-02-13
SG190573A1 (en) 2013-06-28
EP2465523A1 (en) 2012-06-20
PL2465523T3 (pl) 2015-03-31
KR101673889B1 (ko) 2016-11-08
ZA201108446B (en) 2013-01-30
BRPI1012845A2 (pt) 2016-10-11
ES2525448T3 (es) 2014-12-23
EP2432494A2 (en) 2012-03-28
CA2762020A1 (en) 2010-11-25
RS53671B1 (sr) 2015-04-30
JP5784009B2 (ja) 2015-09-24
IL216199A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
UA105290C2 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
EP4414376A3 (en) Novel depsipeptide and uses thereof
HN2012001321A (es) Analogo peptidico de oxintomodulina
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
EA201070271A1 (ru) Пептиды для получения вакцины
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
MX350046B (es) Tratamientos para trastornos gastrointestinales.
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
ECSP10010327A (es) Péptidos del fviii y su uso para hemofílicos tolerantes
BR112015013675A2 (pt) composições compreendendo vortioxetina e donepezil
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης